PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31640425-6	2020	Flavokawain B at low concentration led to increase of caspase-3 activity.	flavokawain B	0-13	caspase 3	Homo sapiens	54-63
32882870-12	2020	FKB+doxorubicin-mediated dysregulated Bax/Bcl-2, Beclin-1/Bcl-2 ratios suggested apoptosis, autophagy induction in AGS cells.	flavokawain B	0-3	BCL2-associated X protein	Mus musculus	38-41
32882870-12	2020	FKB+doxorubicin-mediated dysregulated Bax/Bcl-2, Beclin-1/Bcl-2 ratios suggested apoptosis, autophagy induction in AGS cells.	flavokawain B	0-3	B cell leukemia/lymphoma 2	Mus musculus	42-47
32882870-12	2020	FKB+doxorubicin-mediated dysregulated Bax/Bcl-2, Beclin-1/Bcl-2 ratios suggested apoptosis, autophagy induction in AGS cells.	flavokawain B	0-3	beclin 1, autophagy related	Mus musculus	49-57
32882870-12	2020	FKB+doxorubicin-mediated dysregulated Bax/Bcl-2, Beclin-1/Bcl-2 ratios suggested apoptosis, autophagy induction in AGS cells.	flavokawain B	0-3	B cell leukemia/lymphoma 2	Mus musculus	58-63
34737421-0	2021	Flavokawain B alleviates LPS-induced acute lung injury via targeting myeloid differentiation factor 2.	flavokawain B	0-13	lymphocyte antigen 96	Mus musculus	69-101
34737421-6	2021	Among the screened compounds, flavokawain B (FKB) significantly reduced LPS-induced pro-inflammatory IL-6 secretion in macrophages.	flavokawain B	30-43	interleukin 6	Mus musculus	101-105
34737421-6	2021	Among the screened compounds, flavokawain B (FKB) significantly reduced LPS-induced pro-inflammatory IL-6 secretion in macrophages.	flavokawain B	45-48	interleukin 6	Mus musculus	101-105
34077029-2	2021	The main purpose of the current study was to investigate the anticancer effects of flavokawain-B in gemcitabine-resistant non-small lung cancer cells (NSCLC) along with evaluating its mode of action by studying its effects on programmed cell death, ROS production, cell migration and invasion and PI3K/AKT signalling pathway.	flavokawain B	83-96	AKT serine/threonine kinase 1	Homo sapiens	302-305
34077029-3	2021	METHODS: Cell proliferation rate was studied using MTS cell viability assay while apoptosis induction by flavokawain-B was studied by fluorescence microscopy using DAPI staining as well as flow cytometry using Annexin V-FITC/propidium iodide (PI).	flavokawain B	105-118	annexin A5	Homo sapiens	210-219
34077029-8	2021	DAPI and annexin V-FITC/PI staining showed that flavokawain-B led to a dose-dependent onset of apoptosis in lung cancer cells characterized by shrunken cells, fragmented nuclei and chromatin condensation.	flavokawain B	48-61	annexin A5	Homo sapiens	9-18
34077029-9	2021	Western blot showed that flavokawain-B resulted in downregulation of Bcl-2 and upregulation of Bax in a dose dependent manner.	flavokawain B	25-38	BCL2 apoptosis regulator	Homo sapiens	69-74
34077029-9	2021	Western blot showed that flavokawain-B resulted in downregulation of Bcl-2 and upregulation of Bax in a dose dependent manner.	flavokawain B	25-38	BCL2 associated X, apoptosis regulator	Homo sapiens	95-98
33053749-6	2020	The results convey that FKB inhibited cell viability, B-Raf proto-oncogene, serine/threonine kinase (BRAF)/extracellular signal-regulated kinase (ERK) expression in human melanoma cells.	flavokawain B	24-27	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	101-105
33053749-9	2020	Autophagy inhibitors [3-methyladenine (3-MA)/chloroquine (CQ)] and LC3 silencing suppressed FKB-induced apoptosis by decreasing caspase-3 in melanoma cells.	flavokawain B	92-95	caspase 3	Homo sapiens	128-137
29908094-0	2018	Adenosine 5"-monophosphate-activated protein kinase-dependent mTOR pathway is involved in flavokawain B-induced autophagy in thyroid cancer cells.	flavokawain B	90-103	nucleoprotein TPR	Tribolium castaneum	62-66
32277640-8	2020	DAPI and annexin V-FITC/PI staining showed that flavokawain-B led to a dose-dependent onset of apoptosis in lung cancer cells characterized by shrunken cells, fragmented nuclei and chromatin condensation.	flavokawain B	48-61	annexin A5	Homo sapiens	9-18
32277640-9	2020	Western blot showed that flavokawain-B resulted in downregulation of Bcl-2 and upregulation of Bax in a dose dependent manner.	flavokawain B	25-38	BCL2 apoptosis regulator	Homo sapiens	69-74
32277640-9	2020	Western blot showed that flavokawain-B resulted in downregulation of Bcl-2 and upregulation of Bax in a dose dependent manner.	flavokawain B	25-38	BCL2 associated X, apoptosis regulator	Homo sapiens	95-98
30847898-4	2019	Mitochondrial (caspase-9/-3 and poly ADP ribose polymerase [PARP]) signaling was found to be involved in FKB-induced apoptosis.	flavokawain B	105-108	caspase 9	Homo sapiens	15-24
30847898-4	2019	Mitochondrial (caspase-9/-3 and poly ADP ribose polymerase [PARP]) signaling was found to be involved in FKB-induced apoptosis.	flavokawain B	105-108	poly(ADP-ribose) polymerase 1	Homo sapiens	32-58
30847898-4	2019	Mitochondrial (caspase-9/-3 and poly ADP ribose polymerase [PARP]) signaling was found to be involved in FKB-induced apoptosis.	flavokawain B	105-108	poly(ADP-ribose) polymerase 1	Homo sapiens	60-64
29908094-2	2018	In this study, we report that FKB has profound effects on the metabolic state of human thyroid cancer (TCa) cells, leading to high autophagy flux through upregulation of AMP-activated protein kinase, which in turn inhibits mTOR and activates Beclin-1 in TCa cells.	flavokawain B	30-33	nucleoprotein TPR	Tribolium castaneum	223-227
30025493-4	2018	Approximately 60% of GBM cells became senescent after treatment with FKB as assessed in the senescence-associated (SA)-GLB1/SA-beta-galactosidase assay.	flavokawain B	69-72	galactosidase beta 1	Homo sapiens	119-123
30025493-4	2018	Approximately 60% of GBM cells became senescent after treatment with FKB as assessed in the senescence-associated (SA)-GLB1/SA-beta-galactosidase assay.	flavokawain B	69-72	galactosidase beta 1	Homo sapiens	127-145
30025493-7	2018	Transfection of ATG5 or ATG7 small interfering RNAs (siRNAs) inhibited FKB-induced autophagy in U251 cells.	flavokawain B	71-74	autophagy related 5	Homo sapiens	16-20
30025493-7	2018	Transfection of ATG5 or ATG7 small interfering RNAs (siRNAs) inhibited FKB-induced autophagy in U251 cells.	flavokawain B	71-74	autophagy related 7	Homo sapiens	24-28
30025493-10	2018	Inhibition of autophagy by autophagy inhibitors 3-methyladenine and chloroquine or knockdown of ATG5 or ATG7 caused FKB-treated U251 cells to switch from senescence to apoptosis.	flavokawain B	116-119	autophagy related 5	Homo sapiens	96-100
30025493-10	2018	Inhibition of autophagy by autophagy inhibitors 3-methyladenine and chloroquine or knockdown of ATG5 or ATG7 caused FKB-treated U251 cells to switch from senescence to apoptosis.	flavokawain B	116-119	autophagy related 7	Homo sapiens	104-108
30025493-11	2018	Finally, knockdown of ATG5 or treatment with chloroquine in combination with FKB, significantly inhibited tumor growth in vivo.	flavokawain B	77-80	autophagy related 5	Homo sapiens	22-26
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	30-33	activating transcription factor 4	Homo sapiens	75-79
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	30-33	DNA damage inducible transcript 3	Homo sapiens	80-85
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	30-33	tribbles pseudokinase 3	Homo sapiens	86-91
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	30-33	AKT serine/threonine kinase 1	Homo sapiens	92-95
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	30-33	mechanistic target of rapamycin kinase	Homo sapiens	96-100
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	30-33	ribosomal protein S6 kinase B1	Homo sapiens	101-108
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	186-189	activating transcription factor 4	Homo sapiens	75-79
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	186-189	DNA damage inducible transcript 3	Homo sapiens	80-85
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	186-189	tribbles pseudokinase 3	Homo sapiens	86-91
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	186-189	AKT serine/threonine kinase 1	Homo sapiens	92-95
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	186-189	mechanistic target of rapamycin kinase	Homo sapiens	96-100
30025493-12	2018	Our results demonstrated that FKB induced protective autophagy through the ATF4-DDIT3-TRIB3-AKT-MTOR-RPS6KB1 signaling pathway in GBM cells, indicating that the combination treatment of FKB with autophagy inhibitors may potentially be an effective therapeutic strategy for GBM.	flavokawain B	186-189	ribosomal protein S6 kinase B1	Homo sapiens	101-108
26186269-1	2016	In order to study the structure-activity relationship of Flavokawain B Mannich-based derivatives as acetylcholinesterase (AChE) inhibitors in our recent investigation, 20 new nitrogen-containing chalcone derivatives (4 a-8d) were designed, synthesized, and evaluated for AChE inhibitory activity in vitro.	flavokawain B	57-70	acetylcholinesterase (Cartwright blood group)	Homo sapiens	100-120
29333130-3	2017	Here, curcumin, flavokawain B, and alpinetin were docked against the crystal structure of R273H mutant p53 in silico.	flavokawain B	16-29	tumor protein p53	Homo sapiens	103-106
29333130-4	2017	Consequently, all the compounds bind to the cavity of R273H mutant p53 with a dissociation constant estimated to have 36.57, 70.77, and 75.11 microM for curcumin, flavokawain B, and alpinetin, respectively.	flavokawain B	163-176	tumor protein p53	Homo sapiens	67-70
28374157-5	2017	FKB-induced AGS cell death was characterized by autophagy, not apoptosis, as evidenced by increased LC3-II accumulation, GFP-LC3 puncta and acidic vesicular organelles (AVOs) formation, without resulting procaspase-3/PARP cleavage.	flavokawain B	0-3	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	100-103
28374157-5	2017	FKB-induced AGS cell death was characterized by autophagy, not apoptosis, as evidenced by increased LC3-II accumulation, GFP-LC3 puncta and acidic vesicular organelles (AVOs) formation, without resulting procaspase-3/PARP cleavage.	flavokawain B	0-3	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	125-128
28374157-5	2017	FKB-induced AGS cell death was characterized by autophagy, not apoptosis, as evidenced by increased LC3-II accumulation, GFP-LC3 puncta and acidic vesicular organelles (AVOs) formation, without resulting procaspase-3/PARP cleavage.	flavokawain B	0-3	poly (ADP-ribose) polymerase family, member 1	Mus musculus	217-221
28374157-7	2017	Silencing autophagy inhibitors CQ/3-MA and LC3 (shRNA) significantly reversed the FKB-induced cell death of AGS cells.	flavokawain B	82-85	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	43-46
27458249-6	2017	The results of this study suggest that FKB induced cell death through p21-mediated cell cycle arrest and activation of p38.	flavokawain B	39-42	H3 histone pseudogene 16	Homo sapiens	70-73
27458249-6	2017	The results of this study suggest that FKB induced cell death through p21-mediated cell cycle arrest and activation of p38.	flavokawain B	39-42	mitogen-activated protein kinase 14	Homo sapiens	119-122
28374157-8	2017	FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells.	flavokawain B	0-3	NLR family, pyrin domain containing 1A	Mus musculus	51-54
28374157-8	2017	FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells.	flavokawain B	0-3	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	104-107
28374157-8	2017	FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells.	flavokawain B	0-3	sequestosome 1	Mus musculus	135-138
28374157-8	2017	FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells.	flavokawain B	0-3	sequestosome 1	Mus musculus	139-145
28374157-8	2017	FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells.	flavokawain B	0-3	autophagy related 4B, cysteine peptidase	Mus musculus	158-163
28374157-8	2017	FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells.	flavokawain B	0-3	beclin 1, autophagy related	Mus musculus	179-187
28374157-8	2017	FKB-triggered ROS generation and ROS inhibition by NAC pre-treatment diminished FKB-induced cell death, LC3 conversion, AVO formation, p62/SQSTM1 activation, ATG4B inhibition and Beclin-1/Bcl-2 dysregulation, which indicated ROS-mediated autophagy in AGS cells.	flavokawain B	0-3	B cell leukemia/lymphoma 2	Mus musculus	188-193
28374157-10	2017	Interestingly, FKB-induced autophagy is associated with the suppression of HER-2 and PI3K/AKT/mTOR signaling cascades.	flavokawain B	15-18	erb-b2 receptor tyrosine kinase 2	Mus musculus	75-80
28374157-10	2017	Interestingly, FKB-induced autophagy is associated with the suppression of HER-2 and PI3K/AKT/mTOR signaling cascades.	flavokawain B	15-18	thymoma viral proto-oncogene 1	Mus musculus	90-93
28374157-10	2017	Interestingly, FKB-induced autophagy is associated with the suppression of HER-2 and PI3K/AKT/mTOR signaling cascades.	flavokawain B	15-18	mechanistic target of rapamycin kinase	Mus musculus	94-98
28374157-13	2017	Notably, silencing of LC3 attenuated FKB-induced autophagy in AGS-xenografted tumors.	flavokawain B	37-40	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	22-25
28103302-0	2017	Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells.	flavokawain B	16-29	uridine-cytidine kinase 2	Homo sapiens	111-115
28103302-12	2017	Initial results from in vitro studies have shown the ability of the bioactive compounds of flavokawain B and alpinetin to target UCK2 enzyme specifically, inducing cell cycle arrest and subsequently leading to cancer cell death, possibly through interfering the MDM2-p53 signalling pathway.	flavokawain B	91-104	uridine-cytidine kinase 2	Homo sapiens	129-133
28103302-12	2017	Initial results from in vitro studies have shown the ability of the bioactive compounds of flavokawain B and alpinetin to target UCK2 enzyme specifically, inducing cell cycle arrest and subsequently leading to cancer cell death, possibly through interfering the MDM2-p53 signalling pathway.	flavokawain B	91-104	MDM2 proto-oncogene	Homo sapiens	262-266
28103302-12	2017	Initial results from in vitro studies have shown the ability of the bioactive compounds of flavokawain B and alpinetin to target UCK2 enzyme specifically, inducing cell cycle arrest and subsequently leading to cancer cell death, possibly through interfering the MDM2-p53 signalling pathway.	flavokawain B	91-104	tumor protein p53	Homo sapiens	267-270
24845100-0	2014	The chalcones cardamonin and flavokawain B inhibit the differentiation of preadipocytes to adipocytes by activating ERK.	flavokawain B	29-42	mitogen-activated protein kinase 1	Mus musculus	116-119
25641429-0	2015	Flavokawain B inhibits the growth of acute lymphoblastic leukemia cells via p53 and caspase-dependent mechanisms.	flavokawain B	0-13	tumor protein p53	Homo sapiens	76-79
25641429-5	2015	Furthermore, the enhancement of p53-dependent apoptosis by flavokawain B could be rescued by pifithrin-alpha, a pharmacological inhibitor of p53 transcriptional activity.	flavokawain B	59-72	tumor protein p53	Homo sapiens	32-35
25641429-5	2015	Furthermore, the enhancement of p53-dependent apoptosis by flavokawain B could be rescued by pifithrin-alpha, a pharmacological inhibitor of p53 transcriptional activity.	flavokawain B	59-72	tumor protein p53	Homo sapiens	141-144
25205193-0	2014	Synthesis and acetylcholinesterase inhibitory activity of Mannich base derivatives flavokawain B.	flavokawain B	83-96	acetylcholinesterase (Cartwright blood group)	Homo sapiens	14-34
25205193-1	2014	A novel series of flavokawain B derivatives, chalcone Mannich bases (4-10) were designed, synthesized, characterized, and evaluated for the inhibition activity against acetylcholinesterase (AChE).	flavokawain B	18-31	acetylcholinesterase (Cartwright blood group)	Homo sapiens	168-188
25205193-1	2014	A novel series of flavokawain B derivatives, chalcone Mannich bases (4-10) were designed, synthesized, characterized, and evaluated for the inhibition activity against acetylcholinesterase (AChE).	flavokawain B	18-31	acetylcholinesterase (Cartwright blood group)	Homo sapiens	190-194
24845100-4	2014	In the further study, cardamonin and flavokawain B inhibited lipid accumulation by downregulating the expression of CCAAT/enhancer binding protein (C/EBP)-beta, C/EBPalpha, and peroxisome proliferator-activated receptor-gamma (PPARgamma) at both mRNA and protein levels.	flavokawain B	37-50	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	148-159
24845100-4	2014	In the further study, cardamonin and flavokawain B inhibited lipid accumulation by downregulating the expression of CCAAT/enhancer binding protein (C/EBP)-beta, C/EBPalpha, and peroxisome proliferator-activated receptor-gamma (PPARgamma) at both mRNA and protein levels.	flavokawain B	37-50	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	161-171
24845100-4	2014	In the further study, cardamonin and flavokawain B inhibited lipid accumulation by downregulating the expression of CCAAT/enhancer binding protein (C/EBP)-beta, C/EBPalpha, and peroxisome proliferator-activated receptor-gamma (PPARgamma) at both mRNA and protein levels.	flavokawain B	37-50	peroxisome proliferator activated receptor gamma	Mus musculus	177-225
24845100-4	2014	In the further study, cardamonin and flavokawain B inhibited lipid accumulation by downregulating the expression of CCAAT/enhancer binding protein (C/EBP)-beta, C/EBPalpha, and peroxisome proliferator-activated receptor-gamma (PPARgamma) at both mRNA and protein levels.	flavokawain B	37-50	peroxisome proliferator activated receptor gamma	Mus musculus	227-236
24845100-5	2014	Cardamonin and flavokawain B also increased phosphorylation of extracellular signal-regulated kinase (ERK) in the early phase of adipocyte differentiation.	flavokawain B	15-28	mitogen-activated protein kinase 1	Mus musculus	63-100
24845100-5	2014	Cardamonin and flavokawain B also increased phosphorylation of extracellular signal-regulated kinase (ERK) in the early phase of adipocyte differentiation.	flavokawain B	15-28	mitogen-activated protein kinase 1	Mus musculus	102-105
24845100-7	2014	Moreover, cardamonin and flavokawain B also modulated the secretion of C-reactive protein, dipeptidyl peptidase IV, interleukin-6, tumor necrosis factor-alpha and fibroblast growth factor-21 in mature adipocytes.	flavokawain B	25-38	C-reactive protein, pentraxin-related	Mus musculus	71-89
24845100-7	2014	Moreover, cardamonin and flavokawain B also modulated the secretion of C-reactive protein, dipeptidyl peptidase IV, interleukin-6, tumor necrosis factor-alpha and fibroblast growth factor-21 in mature adipocytes.	flavokawain B	25-38	dipeptidylpeptidase 4	Mus musculus	91-114
24845100-7	2014	Moreover, cardamonin and flavokawain B also modulated the secretion of C-reactive protein, dipeptidyl peptidase IV, interleukin-6, tumor necrosis factor-alpha and fibroblast growth factor-21 in mature adipocytes.	flavokawain B	25-38	interleukin 6	Mus musculus	116-158
24845100-8	2014	CONCLUSIONS: These results indicate that ERK activation and consequent downregulation of adipocyte-specific transcription factors are involved in the inhibitory effects of the chalcones cardamonin and flavokawain B on adipocyte differentiation.	flavokawain B	201-214	mitogen-activated protein kinase 1	Mus musculus	41-44
23764122-7	2013	Apoptosis induced by FKB resulted in activation of Caspase-3/7, -8 and -9 in OS cell lines, 143B and Saos-2.	flavokawain B	21-24	caspase 3	Homo sapiens	51-73
21543203-2	2012	In the present study, we have investigated the antiproliferative and apoptotic effect of flavokawain B (5-20 mug/ml; 17.6-70.4 muM) against human squamous carcinoma (KB) cells.	flavokawain B	89-102	latexin	Homo sapiens	127-130
22729748-0	2012	Flavokawain B induces apoptosis of non-small cell lung cancer H460 cells via Bax-initiated mitochondrial and JNK pathway.	flavokawain B	0-13	BCL2 associated X, apoptosis regulator	Homo sapiens	77-80
22729748-0	2012	Flavokawain B induces apoptosis of non-small cell lung cancer H460 cells via Bax-initiated mitochondrial and JNK pathway.	flavokawain B	0-13	mitogen-activated protein kinase 8	Homo sapiens	109-112
22729748-5	2012	FKB significantly down-regulated survivin and XIAP, and the inhibitory effect induced by FKB was greatly attenuated by through over-expression of survivin or Bax(-/-) MEFs.	flavokawain B	0-3	X-linked inhibitor of apoptosis	Homo sapiens	46-50
22729748-5	2012	FKB significantly down-regulated survivin and XIAP, and the inhibitory effect induced by FKB was greatly attenuated by through over-expression of survivin or Bax(-/-) MEFs.	flavokawain B	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	158-161
21543203-4	2012	Apoptosis induced by flavokawain B results in activation of caspase-9, -3 and -8, cleavage of poly ADP ribose polymerase (PARP) and Bid in KB cells.	flavokawain B	21-34	caspase 9	Homo sapiens	60-80
21543203-4	2012	Apoptosis induced by flavokawain B results in activation of caspase-9, -3 and -8, cleavage of poly ADP ribose polymerase (PARP) and Bid in KB cells.	flavokawain B	21-34	poly(ADP-ribose) polymerase 1	Homo sapiens	94-120
21543203-4	2012	Apoptosis induced by flavokawain B results in activation of caspase-9, -3 and -8, cleavage of poly ADP ribose polymerase (PARP) and Bid in KB cells.	flavokawain B	21-34	poly(ADP-ribose) polymerase 1	Homo sapiens	122-126
21543203-4	2012	Apoptosis induced by flavokawain B results in activation of caspase-9, -3 and -8, cleavage of poly ADP ribose polymerase (PARP) and Bid in KB cells.	flavokawain B	21-34	BH3 interacting domain death agonist	Homo sapiens	132-135
21543203-5	2012	Flavokawain B also down-regulate Bcl-2 with concomitant increase in Bax level, which resulted in release of cytochrome c.	flavokawain B	0-13	BCL2 apoptosis regulator	Homo sapiens	33-38
21543203-5	2012	Flavokawain B also down-regulate Bcl-2 with concomitant increase in Bax level, which resulted in release of cytochrome c.	flavokawain B	0-13	BCL2 associated X, apoptosis regulator	Homo sapiens	68-71
21543203-5	2012	Flavokawain B also down-regulate Bcl-2 with concomitant increase in Bax level, which resulted in release of cytochrome c.	flavokawain B	0-13	cytochrome c, somatic	Homo sapiens	108-120
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	cyclin A2	Homo sapiens	119-127
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	cyclin B1	Homo sapiens	129-138
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	cyclin dependent kinase 1	Homo sapiens	140-144
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	cell division cycle 25C	Homo sapiens	149-155
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	cyclin dependent kinase inhibitor 1A	Homo sapiens	173-176
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	cyclin dependent kinase inhibitor 1A	Homo sapiens	177-181
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	WEE1 G2 checkpoint kinase	Homo sapiens	183-187
21543203-7	2012	We also observed that flavokawain B caused the G2/M phase arrest that was mediated through reductions in the levels of cyclin A, cyclin B1, Cdc2 and Cdc25C and increases in p21/WAF1, Wee1 and p53 levels.	flavokawain B	22-35	tumor protein p53	Homo sapiens	192-195
21543203-8	2012	Moreover, flavokawain B significantly inhibits matrix metalloproteinase-9 and urokinase plasminogen activator expression, whereas tissue inhibitor of matrix metalloproteinase-1 and plasminogen activator inhibitor-1 were increased, which are playing critical role in tumor metastasis.	flavokawain B	10-23	matrix metallopeptidase 9	Homo sapiens	47-73
22324429-4	2012	Moreover, FKB treatment resulted in the induction of apoptosis, which was associated with DNA fragmentation, mitochondria dysfunction, cytochrome c and AIF release, caspase-3 and caspase-9 activation, and Bcl-2/Bax dysregulation.	flavokawain B	10-13	cytochrome c, somatic	Homo sapiens	135-147
22324429-0	2012	The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway.	flavokawain B	13-26	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	96-101
22324429-0	2012	The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway.	flavokawain B	13-26	AKT serine/threonine kinase 1	Homo sapiens	175-178
22324429-4	2012	Moreover, FKB treatment resulted in the induction of apoptosis, which was associated with DNA fragmentation, mitochondria dysfunction, cytochrome c and AIF release, caspase-3 and caspase-9 activation, and Bcl-2/Bax dysregulation.	flavokawain B	10-13	caspase 3	Homo sapiens	165-174
22324429-0	2012	The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway.	flavokawain B	13-26	mitogen-activated protein kinase 14	Homo sapiens	179-182
22324429-4	2012	Moreover, FKB treatment resulted in the induction of apoptosis, which was associated with DNA fragmentation, mitochondria dysfunction, cytochrome c and AIF release, caspase-3 and caspase-9 activation, and Bcl-2/Bax dysregulation.	flavokawain B	10-13	caspase 9	Homo sapiens	179-188
22324429-4	2012	Moreover, FKB treatment resulted in the induction of apoptosis, which was associated with DNA fragmentation, mitochondria dysfunction, cytochrome c and AIF release, caspase-3 and caspase-9 activation, and Bcl-2/Bax dysregulation.	flavokawain B	10-13	BCL2 apoptosis regulator	Homo sapiens	205-210
22324429-4	2012	Moreover, FKB treatment resulted in the induction of apoptosis, which was associated with DNA fragmentation, mitochondria dysfunction, cytochrome c and AIF release, caspase-3 and caspase-9 activation, and Bcl-2/Bax dysregulation.	flavokawain B	10-13	BCL2 associated X, apoptosis regulator	Homo sapiens	211-214
22324429-9	2012	The profound reduction in cell number was observed in combination treatment with FKB and Akt/p38 MAPK inhibitors, indicating that the disruption of Akt and p38 MAPK cascades plays a functional role in FKB-induced G(2)/M arrest and apoptosis in HSC-3 cells.	flavokawain B	81-84	AKT serine/threonine kinase 1	Homo sapiens	148-151
22324429-9	2012	The profound reduction in cell number was observed in combination treatment with FKB and Akt/p38 MAPK inhibitors, indicating that the disruption of Akt and p38 MAPK cascades plays a functional role in FKB-induced G(2)/M arrest and apoptosis in HSC-3 cells.	flavokawain B	201-204	AKT serine/threonine kinase 1	Homo sapiens	89-92
22324429-9	2012	The profound reduction in cell number was observed in combination treatment with FKB and Akt/p38 MAPK inhibitors, indicating that the disruption of Akt and p38 MAPK cascades plays a functional role in FKB-induced G(2)/M arrest and apoptosis in HSC-3 cells.	flavokawain B	201-204	mitogen-activated protein kinase 14	Homo sapiens	93-96
22324429-9	2012	The profound reduction in cell number was observed in combination treatment with FKB and Akt/p38 MAPK inhibitors, indicating that the disruption of Akt and p38 MAPK cascades plays a functional role in FKB-induced G(2)/M arrest and apoptosis in HSC-3 cells.	flavokawain B	201-204	AKT serine/threonine kinase 1	Homo sapiens	148-151
22324429-9	2012	The profound reduction in cell number was observed in combination treatment with FKB and Akt/p38 MAPK inhibitors, indicating that the disruption of Akt and p38 MAPK cascades plays a functional role in FKB-induced G(2)/M arrest and apoptosis in HSC-3 cells.	flavokawain B	201-204	mitogen-activated protein kinase 14	Homo sapiens	156-159
22324429-9	2012	The profound reduction in cell number was observed in combination treatment with FKB and Akt/p38 MAPK inhibitors, indicating that the disruption of Akt and p38 MAPK cascades plays a functional role in FKB-induced G(2)/M arrest and apoptosis in HSC-3 cells.	flavokawain B	201-204	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	244-249
20112340-0	2010	Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth.	flavokawain B	0-13	BCL2-like 11 (apoptosis facilitator)	Mus musculus	92-95
22115332-0	2011	Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression.	flavokawain B	0-13	BCL2 related protein A1	Homo sapiens	68-73
22115332-0	2011	Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression.	flavokawain B	0-13	BCL2 like 11	Homo sapiens	101-104
22115332-0	2011	Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression.	flavokawain B	0-13	BCL2 apoptosis regulator	Homo sapiens	128-133
22115332-2	2011	In this study, we have assessed the antitumor potential and molecular mechanisms of flavokawain B (FKB) as a kava chalcone on the ACC-2 cell line in vitro.	flavokawain B	84-97	BCL2 related protein A1	Homo sapiens	130-135
22115332-2	2011	In this study, we have assessed the antitumor potential and molecular mechanisms of flavokawain B (FKB) as a kava chalcone on the ACC-2 cell line in vitro.	flavokawain B	99-102	BCL2 related protein A1	Homo sapiens	130-135
22115332-6	2011	Among them, Bim expression was significantly induced by FKB, and knockdown of Bim expression by short-hairpin RNAs attenuated the inhibitory effect induced by FKB on ACC-2 cells.	flavokawain B	56-59	BCL2 like 11	Homo sapiens	12-15
20112340-4	2010	FKB induces apoptosis with an associated increased expression of proapoptotic proteins: death receptor-5, Bim and Puma and a decreased expression of inhibitors of apoptosis protein: XIAP and survivin.	flavokawain B	0-3	BCL2-like 11 (apoptosis facilitator)	Mus musculus	106-109
20112340-6	2010	Knockdown of Bim expression by short-hairpin RNAs attenuates the inhibitory effect on anchorage-dependent and -independent growth and caspase cleavages induced by FKB.	flavokawain B	163-166	BCL2-like 11 (apoptosis facilitator)	Mus musculus	13-16
20112340-9	2010	Furthermore, FKB treatment of mice bearing DU145 xenograft tumors results in tumor growth inhibition and increases Bim expression in tumor tissues.	flavokawain B	13-16	BCL2-like 11 (apoptosis facilitator)	Mus musculus	115-118
20398749-0	2010	Flavokawain B, a novel chalcone from Alpinia pricei Hayata with potent apoptotic activity: Involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116 cells.	flavokawain B	0-13	DNA damage inducible transcript 3	Homo sapiens	114-121
20398749-4	2010	Flavokawain B exerts its apoptotic action through ROS generation and GADD153 up-regulation, which lead to mitochondria-dependent apoptosis characterized by release of cytochrome c and translocation of Bak.	flavokawain B	0-13	DNA damage inducible transcript 3	Homo sapiens	69-76
20398749-4	2010	Flavokawain B exerts its apoptotic action through ROS generation and GADD153 up-regulation, which lead to mitochondria-dependent apoptosis characterized by release of cytochrome c and translocation of Bak.	flavokawain B	0-13	cytochrome c, somatic	Homo sapiens	167-179
20398749-5	2010	The up-regulation of GADD153 in flavokawain B-treated HCT116 cells is associated with mitochondrial dysfunction and altered expression of Bcl-2 family members.	flavokawain B	32-45	DNA damage inducible transcript 3	Homo sapiens	21-28
20398749-5	2010	The up-regulation of GADD153 in flavokawain B-treated HCT116 cells is associated with mitochondrial dysfunction and altered expression of Bcl-2 family members.	flavokawain B	32-45	BCL2 apoptosis regulator	Homo sapiens	138-143
20398749-6	2010	Moreover, pretreatment with the ROS scavenger N-acetylcysteine abolishes flavokawain B-induced ROS generation, GADD153 up-regulation, and apoptosis.	flavokawain B	73-86	DNA damage inducible transcript 3	Homo sapiens	111-118
20398749-7	2010	Similarly, RNAi-mediated gene silencing reduced flavokawain B-enhanced expression of GADD153 and apoptotic Bim, leading to diminished apoptosis.	flavokawain B	48-61	DNA damage inducible transcript 3	Homo sapiens	85-92
20398749-9	2010	Taken together, our data provide evidence for a molecular mechanism to explain the apoptotic activity of Alpinia plants, showing that flavokawain B acts through ROS generation and GADD153 up-regulation to regulate the expression of Bcl-2 family members, thereby inducing mitochondrial dysfunction and apoptosis in HCT116 cells.	flavokawain B	134-147	DNA damage inducible transcript 3	Homo sapiens	180-187
20398749-9	2010	Taken together, our data provide evidence for a molecular mechanism to explain the apoptotic activity of Alpinia plants, showing that flavokawain B acts through ROS generation and GADD153 up-regulation to regulate the expression of Bcl-2 family members, thereby inducing mitochondrial dysfunction and apoptosis in HCT116 cells.	flavokawain B	134-147	BCL2 apoptosis regulator	Homo sapiens	232-237
19537711-5	2009	Expression of iNOS and COX-2 proteins was also inhibited by FKB in a dose-dependent manner.	flavokawain B	60-63	nitric oxide synthase 2, inducible	Mus musculus	14-18
19537711-5	2009	Expression of iNOS and COX-2 proteins was also inhibited by FKB in a dose-dependent manner.	flavokawain B	60-63	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28